Arcturus Therapeutics, Inc.

100 articles with Arcturus Therapeutics, Inc.

• Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

  3/7/2023

  Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.

• Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis

  1/31/2023

  Arcturus Therapeutics Holdings Inc. today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.

• Arcturus Appoints John Markels, Ph.D. to its Board of Directors

  12/13/2022

  Arcturus Therapeutics Holdings Inc. today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors.

• CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

  12/12/2022

  CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT).

• Arcturus Therapeutics to Present at the Following Investor Conferences in November 2022

  11/7/2022

  Arcturus Therapeutics Holdings Inc., a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will present at the following investor conferences.

• 

  CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal

  11/2/2022

  San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.

• Arcturus Therapeutics to Attend the Following September 2022 Investor Conferences

  9/1/2022

  Arcturus Therapeutics Holdings Inc., a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will participate in the following investor conferences.

• Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

  8/9/2022

  Arcturus Therapeutics Holdings Inc., a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates.

• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 22, 2022

  6/22/2022

  Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 48,200 shares of Arcturus common stock to seven newly-hired employees.

• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21, 2022

  5/21/2022

  Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 38,800 shares of Arcturus common stock to five newly-hired employees.

• Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

  5/9/2022

  Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2022, and provided corporate updates.

• CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

  5/5/2022

  Arcturus Therapeutics Holdings Inc. provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose booster.

• Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

  4/27/2022

  Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter ended March 31, 2022 after the market close on Monday, May 9 and will also host a conference call and webcast at 4:30 pm Eastern Daylight Time on May 9, 2022.

• 

  Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More

  4/25/2022

  It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.

• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 23, 2022

  4/23/2022

  Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 60,400 shares of Arcturus common stock to four newly-hired employee.

• Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

  4/20/2022

  Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.

• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 19, 2022

  3/19/2022

  Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 20,000 shares of Arcturus’ common stock to two newly-hired employee.

• Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

  3/14/2022

  Arcturus Therapeutics Holdings Inc. announced that Company management will participate in a Fireside Chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 1:35 p.m. ET.

• 

  Five Top CEOs to Watch in 2022

  2/23/2022

  Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.

• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  2/19/2022

  Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 11,200 shares of Arcturus’s common stock to three newly-hired employees.